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Available online 26 March 2015AbstractAim: The aim of present study is to evaluate the effect of b-caryophyllene (BCP), on deranged plasma and tissue glycoprotein components in
streptozotocin-induced diabetic rats.
Methods: Diabetes was induced in overnight fasted experimental rats by a single intraperitoneal (i.p) injection of STZ (40 mg/kg b.w) dissolved
in 0.1 M citrate buffer (pH 4.5). After the induction of diabetes, animals were treated orally with BCP (200 mg/kg b.w) and glibenclamide
(600 mg/kg b.w) for 45 days.
Results: A significant increase in glycoprotein components such as hexose, hexosamine, fucose and sialic acid in plasma was noticed in diabetic
rats. In hepatic and renal tissues, a significant decrease in sialic acid with increase in other glycoprotein components was observed in diabetic rats
when compared with control rats. Oral administration of BCP and glibenclamide significantly reversed the glycoprotein levels in plasma and
tissues of diabetic rats to near normal.
Conclusion: From this study, we conclude that BCP ameliorates deranged glycoprotein metabolism in streptozotocin-induced diabetic rats.
Copyright © 2015, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Diabetes mellitus is a metabolic disorder characterized by
hyperglycemia with disturbances of carbohydrate, fat and
protein metabolism resulting from defects in insulin secretion,
insulin action or both.1 It is a serious and progressive disorder
affecting approximately 60% of the Asian population and
according to World Health Organization, the number of dia-
betic patients is expected to increase 366 million or more by
the year 2030.2,3 Hyperglycemia and insulin deficiency, the
hallmarks of diabetes mellitus alters glycoprotein components
in various tissues. Several studies reported that impaired* Corresponding author.
E-mail address: sankarhari05@gmail.com (C. Sankaranarayanan).
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2211-5587/Copyright © 2015, Taiwan Society of Emergency Medicine. Publishedmetabolism of glycoproteins plays a major role in the patho-
genesis of diabetic complications.
Glycoproteins are conjugated proteins that contain one or
more covalently linked carbohydrate chains which contribute
to the structure of extracellular matrix in animal cells.4 Hex-
ose, hexosamine and sialic acid are the basic components of
cell surface glycoproteins which play important roles in cell
differentiation and recognition, adhesion of macromolecules
to the cell surface and in secretion and absorption of macro-
molecules.5 They also serve numerous biological functions
like blood group antigens, enzymes and transporters.6
Derangement in the metabolism of hexose, hexosamine,
fucose and sialic acid has been observed in naturally occurring
and in experimental diabetes. Various studies have suggested
that alteration in glycoprotein components could be a conse-
quence of impaired carbohydrate metabolism.7, 8by Elsevier Taiwan LLC. All rights reserved.
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various diseases due to their efficacy and non-toxic nature.
Beta-caryophyllene (BCP; Fig.1), a sesquiterpene lactone
present in the essential oil of several Indian and Chinese spices
such as cloves (Syzygium aromaticum), oregano (Origanum
vulgare), thyme (Thymus vulgaris), black pepper (Piper nig-
rum), cinnamon (Cinnamomum cassia) and Bupleurum
bicaule possess diverse pharmacological activities such as
antioxidant, anti-inflammatory, anticancer and immunomodu-
latory properties.9-12 Recently, we studied the antidiabetic
effects of BCP in streptozotocin (STZ) induced diabetic rats.
BCP exhibits a dose dependent response in glycaemic con-
trol.13 As several studies show that STZ induced diabetic rats
exhibit alteration in glycoprotein components in 45 days, the
present study is aimed to assess the effect of BCP on glyco-
protein components in STZ-induced type 2 diabetic rats.
2. Materials and methods2.1. ChemicalsBCP and STZ were purchased from Sigma-Aldrich (St.
Louis, MO, USA). All other chemicals were purchased from
standard commercial suppliers and were of analytical grade.2.2. AnimalsAdult male albino Wistar rats weighing 180-200 g were
obtained from Central Animal House, Department of Experi-
mental Medicine, Rajah Muthiah Medical College and Hos-
pital (RMMCH), Annamalai University, Tamil Nadu, India.
They were maintained at a constant temperature (25 ± 2C) on
a 12 h light/dark cycle. The rats were fed with a commercial
pellet diet (Hindustan Lever Ltd., Bangalore, India) and water
ad libitum. Experiments were conducted according to the
ethical norms approved by the Institutional Animal Ethics
Committee of RMMCH (Reg No. 160/1999/CPCSEA, Pro-
posal No.: 991), Annamalai University. The rats were accli-
matized for a week before starting the experiments.2.3. Experimental induction of type 2 diabetesDiabetes was induced in overnight fasted rats by a single
intraperitoneal (i.p) injection of STZ (40 mg/kg b.w.) dis-
solved in 0.1 M citrate buffer (pH 4.5).14 STZ injected animals
were given 20% glucose solution overnight to overcome drug-
induced hypoglycemy. Control rats were injected with the
same volume of isotonic saline. After 72 h, plasma glucoseFig.1. Structure of b-Caryophyllene.was determined and those rats with fasting glucose levels
>250 mg/dl were used in the present study.2.4. Experimental designExperimental rats were divided into five groups, comprising
six animals in each group (18 diabetic surviving rats, 12
normal control rats). BCP was dissolved in corn oil and
administered orally using an intragastric tube for a period of
45 days.
Group 1: Normal control (vehicle treated)
Group 2: Normal þ BCP (200 mg/kg b.w)13
Group 3: Diabetic control (vehicle treated)
Group 4: Diabetic þ BCP (200 mg/kg b.w)
Group 5: Diabetic þ glibenclamide (600 mg/kg b.w)15
After the experimental period, rats were fasted overnight,
anesthetized using ketamine (24 mg/kg b.w. intramuscular
injection) and sacrificed by cervical decapitation. Hepatic and
renal tissues were dissected, washed immediately in ice-cold
saline and homogenized in Tris-HCl buffer (0.1M, pH 7.5).2.5. Extraction of glycoproteinsTo 0.1 ml of plasma, 5.0 ml of methanol was added, mixed
well and centrifuged for 10 minutes at 3000g. The supernatant
was decanted and the precipitate was again washed with
5.0 ml of 95% ethanol, recentrifuged and the supernatant was
decanted to obtain the precipitate of glycoproteins which was
used for the estimation of glycoprotein components.
Tissues were defatted by the method of Folch et al.16 for the
estimation of glycoproteins. A known weight of the tissue was
homogenized in 7.0 ml of methanol. The contents were filtered
and homogenized with 14.0 ml of chloroform. This was
filtered and the residue was successively homogenized in
chloroform-methanol (2:1, v/v) and each time the extract was
filtered. The residue (defatted tissues) was obtained and the
filtrate decanted. A weighed amount of defatted tissue was
suspended in 3.0 ml of 2 N HCl and heated at 90C for
4 hours. The sample was cooled and neutralized with 3.0 ml of
2 N NaOH. Aliquots from this were used for estimation of
fucose, hexose, hexosamine and sialic acid.2.6. Biochemical analysis
2.6.1. Determination of plasma glucose and insulin
Glucose was estimated using a commercial kit method of
Trinder.17 Plasma insulin was assayed by an enzyme linked
immunosorbent assay (ELISA) using a Boehrin-
gereMannheim commercial kit by the method of Burgi.18
2.6.2. Determination of glycoprotein levels
Hexose was estimated by the method of Niebes.19 The re-
action mixture contained 0.5 ml of tissue homogenate/plasma,
0.5 ml of 5% phenol and 2.5 ml of concentrated H2SO4 and
was boiled for 20 minutes and absorbance was read at 490 nm.
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Morgan20 with slight modifications by Niebes.19 Briefly, the re-
actionmixture contained 0.5ml plasma/1.0ml tissue homogenate
and 2.5 ml of 3N HCl. It was boiled for 6 hours and neutralized
with 6N NaOH. To 0.8 ml of the neutralized sample was added
0.6 ml of acetyl acetone reagent and boiled for 30 minutes. The
mixture was treated with 2.0 ml of Ehrlich's reagent. The color
developed was read at 540 nm colorimetrically.
Sialic acid (SA) was determined by the method of Warren.21
In brief, 0.5 ml of tissue homogenate/plasma was treated with
0.5 ml of de-ionized water and 0.25 ml of periodic acid and
incubated at 37C for 30 minutes. Then, 0.2 ml of sodium meta-
arsenate and 2.0 ml of thiobarbituric acid were added to the re-
action mixture which was heated for 6 minutes; 5.0 ml of acid-
ified butanolwas then added and absorbancewas read at 540 nm.
Fucose was estimated by the method of Dische and Shet-
tle.22 Briefly 0.5 ml of tissue homogenate/plasma was treated
with 4.5 ml of H2SO4 and boiled for 3 minutes; 0.1 ml of
cysteine hydrochloride reagent was then added. After 75 mi-
nutes in the dark, absorbance was read at 393 and 430 nm. The
glycoprotein levels were expressed as mg/100 g for defatted
tissue and mg/dl for plasma.2.7. Statistical analysisThe experimental results were expressed as mean ± SD and
subjected to one-way analysis of variance (ANOVA), using
IBM SPSS Statistics 22.0 (IBM Corp., Armonk, NY, USA)
and the comparisons of significant differences among the
groups were performed using Duncan's post hoc multiple
range test (DMRT); p < 0.05 was considered as significantly
different between means.
3. Results
The effect of BCP on blood glucose and insulin in control
and experimental diabetic rats were shown in Fig. 2. Glucosea
a
b
a a
b
0
2
4
6
8
10
12
14
16
18
20
NC                  N + BCP               
(200 mg/kg b.w)
 DC
Group
In
su
lin
 (μ
U
/m
l)
Insulin
Fig.2. Changes in the levels of blood glucose and insulin of normal and experim
superscript differ significantly at p < 0.05 (DMRT).levels were elevated and the plasma insulin was significantly
decreased in diabetic rats compared with normal rats. Oral
administration of BCP at 200 mg/kg b.w. to diabetic rats for
45 days decreased blood glucose and increased plasma insulin
to near normal, which was comparable with glibenclamide.
The plasma glucose and insulin levels of normal rats were not
altered when administered with BCP. (Values are given in
appendix Table 1).
Table 2 shows the changes in the levels of hexose, hexos-
amine, fucose and sialic acid in plasma of control and
experimental rats. There was a significant increase in plasma
glycoproteins in diabetic rats when compared to normal con-
trol rats. Administration of BCP to diabetic rats resulted in
significant reduction of glycoproteins in plasma which is
comparable with glibenclamide.
The levels of glycoproteins in liver and kidney tissues of
control and experimental rats were shown in Tables 3 and 4.
The levels of SA were significantly decreased in the tissues of
diabetic rats, whereas an increase in protein-bound hexose,
hexosamine and fucose were observed. Oral administration of
BCP to diabetic rats significantly reversed these changes in
tissues to near normal which is comparable with
glibenclamide.
4. Discussion
Diabetes mellitus is a metabolic disorder of multiple eti-
ologies that has reached pandemic proportions worldwide.
Persistent hyperglycemia damages pancreatic b-cell resulting
in impaired insulin secretion and action thus affecting glucose
utilization in peripheral tissues.23 Various studies have sug-
gested that hyperglycemia-induces cell damage via increased
flux of glucose through polyol and hexosamine pathway, non-
enzymatic glycation of proteins and through activation of
protein kinase C isoforms.5, 24
Sustained hyperglycemia increases the expression of
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ental rats. Values are mean ± SD for six rats. Values not sharing a common
Table 1
The levels of fasting plasma glucose and insulin in normal and diabetic rats.
Groups Glucose (mg/dl) Insulin (mU/ml)
Normal control 96.45 ± 7.93a 16.58 ± 1.42a
Normal þ BCP (200 mg/kg b.w) 93.62 ± 8.72a 17.27 ± 1.27a
Diabetic control 293.46 ± 25.23b 7.23 ± 0.57b
Diabetic þ BCP (200 mg/kg b.w) 117.51 ± 9.96c 14.28 ± 1.19c
Diabetic þ glibenclamide
(600 mg/kg b.w)
115.05 ± 9.41d 15.06 ± 1.33dc
Values are mean ± SD for six rats. Values not sharing a common superscript
differ significantly at p < 0.05 (DMRT).
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increase in the levels of hexose and hexosamine in plasma and
tissues.25 Protein-bound hexose contributes hydrophilic nature
to the cell membrane and hexosamine through its cationic
charges makes cell membrane polarized.26 The increased flux
of glucose through hexosamine pathway causes insulin resis-
tance and vascular complications.27 In our study, diabetic rats
showed increased levels of hexose and hexosamine in plasma,
hepatic and renal tissues. Administration of BCP to diabetic
rats significantly reduced their levels to near normal. Our re-
sults are in concordance with Sankaranarayanan and Pari,6
who reported that administration of thymoquinone improved
hexose and hexosamine levels in diabetic rats.
SA is an acetylated derivative of neuraminic acid and is an
essential component of glycoproteins and glycolipids.
Vascular endothelium carries a high concentration of sialic
acid where it governs permeability. It is necessary for the cell-
surface residency of platelet and promotes endothelial barrier
integrity.28 It also acts as a co-factor of many cell receptors
and is positively associated with most of the serum acute phase
reactants.29 In diabetic state, extensive micro vascular damageTable 2
Effect of BCP on plasma glycoproteins in normal and experimental rats.
Groups Hexose
(mg/dl)
Normal control 84.11 ± 6.43a
Normal þ BCP
(200 mg/kg b.w)
82.94 ± 6.04a
Diabetic control 125.87 ± 9.85b
Diabetic þ BCP (200 mg/kg b.w) 107.41 ± 7.91c
Diabetic þ glibenclamide(600 mg/kg b.w) 98.12 ± 7.43d
Values are mean ± SD for six rats.
Values not sharing a common superscript differ significantly at p < 0.05 (DMRT)
Table 3
Changes in the level of liver glycoproteins in normal and experimental rats.
Groups Hexose
(mg/dl)
Normal control 31.27 ± 2.45a
Normal þ BCP
(200 mg/kg b.w)
30.24 ± 2.24a
Diabetic control 53.37 ± 4.76b
Diabetic þ BCP (200 mg/kg b.w) 42.80 ± 3.44c
Diabetic þ glibenclamide (600 mg/kg b.w) 37.98 ± 2.94d
Values are mean ± SD for six rats.
Values not sharing a common superscript differ significantly at p < 0.05 (DMRT)sheds sialic acid into circulation.30 Several studies have
highlighted that sialic acid metabolism is drastically altered in
diabetic condition. Such an elevation of sialic acid level in the
plasma leads to complications like retinopathy, nephropathy
and neuropathy. A recent study of Prajna et al.31 states that
increased SA is a potential risk factor for development of
nephropathy in diabetic patients. Similarly raised levels of
serum SA is implicated in cardiovascular diseases.7 However,
decreased level of sialic acid is observed in the tissues of
diabetic rats which may be related to increased synthesis of
fibronectin, which contains sialic acid in its core structure.
Further, the decreased tissue sialic acid levels is associated
with oxidative stress induced desialylation of glycoproteins.32
In our study, a significant elevation in plasma sialic acid with a
fall in hepatic and renal tissues was observed in diabetic
control rats. Oral administration of BCP to diabetic treated rats
significantly restored the levels of SA in plasma, hepatic and
renal tissues to near normal which is comparable with
glibenclamide.
L-fucose, a deoxyhexose is a component of many N- and
O-linked glycoproteins and participates in many biological
recognition events. Fucose and sialic acid form specific
structures called glycanic chains covalently linked to lipids or
proteins which are present on the cell surface.8 Fucosylated
glycans are synthesized from fucosyl transferase and have
important roles in selectin-mediated leukocyte-endothelial
adhesion and in blood transfusion reactions.33 In diabetic state,
the levels of fucose is significantly increased which may be
due to the increased activities of fucosidase and fucosyl
transferase.34 In our study, an elevated level of fucose was
observed in diabetic rats, which on treatment with BCP
significantly reduced which is comparable with glibenclamide.Hexosamine
(mg/dl)
Fucose
(mg/dl)
Sialic acid
(mg/dl)
65.42 ± 4.54a 34.53 ± 2.58a 54.72 ± 4.38a
64.91 ± 5.10a 31.90 ± 2.75a 53.79 ± 4.18a
89.64 ± 7.12b 49.86 ± 3.77b 73.96 ± 6.06b
75.10 ± 7.02c 41.89 ± 3.35c 65.73 ± 4.10c
72.97 ± 6.08c 38.22 ± 2.31d 60.15 ± 3.05d
.
Hexosamine
(mg/dl)
Fucose
(mg/dl)
Sialic acid
(mg/dl)
16.85 ± 1.32a 12.73 ± 1.21a 8.66 ± 0.62a
15.67 ± 1.26a 11.92 ± 1.14a 8.59 ± 0.60a
31.88 ± 2.43b 23.66 ± 2.20b 4.28 ± 0.30b
23.03 ± 1.71c 18.37 ± 1.41c 6.89 ± 0.55c
20.82 ± 1.34d 16.52 ± 1.15d 7.71 ± 0.68d
.
Table 4
Changes in the level of renal glycoproteins in normal and experimental rats.
Groups Hexose
(mg/dl)
Hexosamine
(mg/dl)
Fucose
(mg/dl)
Sialic acid
(mg/dl)
Normal control 23.54 ± 2.16a 14.16 ± 0.90a 11.50 ± 0.89a 6.87 ± 0.53a
Normal þ BCP
(200 mg/kg b.w)
22.06 ± 1.66a 13.88 ± 1.06a 11.16 ± 0.93a 6.93 ± 0.60a
Diabetic control 45.32 ± 3.88b 25.18 ± 2.32b 26.42 ± 2.19b 4.01 ± 0.36b
Diabetic þ BCP (200 mg/kg b.w) 29.89 ± 2.11c 18.52 ± 2.32c 16.70 ± 1.23c 6.18 ± 0.57c
Diabetic þ glibenclamide (600 mg/kg b.w) 26.87 ± 2.09d 15.89 ± 1.17d 14.83 ± 1.08d 6.41 ± 0.38ac
Values are mean ± SD for six rats.
Values not sharing a common superscript differ significantly at p < 0.05 (DMRT).
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esis in hepatic and renal tissues under diabetic state signifi-
cantly channelizes glucose through insulin independent
pathway contributing to the exaggerated synthesis of glyco-
proteins.8,24 As insulin governs glucose production and utili-
zation, enhancement in insulin secretion and action will
improve glycoprotein metabolism in the diabetic state. In our
study we observed that oral administration of BCP increased
insulin with concomitant decrease in glucose levels in diabetic
rats. An enhancement in plasma insulin levels in BCP treated
rats signifies its insulinotropic property. In our previous study
we noticed an increase in insulin positive b-cells in BCP
treated diabetic rats.13 Recently, Suijun et al.35 reported that
trans-caryophyllene activates small G proteins such as Arf6,
Rac1 and Cdc42 and promotes glucose-stimulated insulin
secretion in MIN6 cell lines.
Thus the observed increase in plasma insulin levels
significantly ameliorated glycoprotein components in plasma
and tissues of diabetic rats. Our results are in harmony with,
Sundaram et al.5 who reported that iridoid glycoside improved
insulin secretion and brought significant alteration in glyco-
protein components in plasma, hepatic and renal tissues of
diabetic rats.
5. Conclusion
From the above findings, we conclude that BCP amelio-
rated glycoproteins components in STZ-induced diabetic rats.
BCP through its insulinotropic effect on remnant pancreatic b-
cells reversed the altered glycoprotein levels in plasma, he-
patic and renal tissues of diabetic rats and thus serves as a
promising agent in the management of diabetes mellitus.
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